Skip to main content
Journal of Clinical Medicine logoLink to Journal of Clinical Medicine
. 2024 Feb 9;13(4):1002. doi: 10.3390/jcm13041002

Reply to Su et al. Comment on “Matsumoto et al. Remimazolam’s Effects on Postoperative Nausea and Vomiting Are Similar to Those of Propofol after Laparoscopic Gynecological Surgery: A Randomized Controlled Trial. J. Clin. Med. 2023, 12, 5402”

Ayumu Matsumoto 1,, Shiho Satomi 1,, Nami Kakuta 2, Soshi Narasaki 1, Yukari Toyota 1, Hirotsugu Miyoshi 1, Yousuke T Horikawa 1, Noboru Saeki 1, Katsuya Tanaka 2, Yasuo M Tsutsumi 1,*
Editors: Emmanuel Andrès, Won Ho Kim
PMCID: PMC10889432  PMID: 38398315

We thank the authors for their insightful and thoughtful commentary on our recent publication [1]. We calculated the sample size based on the data comparing the incidence of PONV between sevoflurane and propofol because remimazolam is a new intravenous anesthetic approved for the first time in the world in Japan in 2020 for general anesthesia and we could not find data on PONV caused by total intravenous anesthesia except for propofol at that time. We revealed the incidence of PONV caused by remimazolam compared to propofol, and the odds ratio was 1. This result suggests there was no difference in the incidence of PONV between remimazolam and propofol. Therefore, we believe that our small sample size contributed very little to the result indicating there was no significant difference in the incidence of PONV in this study.

According to guidelines for the management of PONV, perioperative fasting has an uncertain significance, and the occurrence of intraoperative hypotension was not included in the risk factors for PONV [2]. We defined intraoperative hypotension to set criteria for the administration of ephedrine during general anesthesia.

For postoperative analgesia, non-opioid analgesics were also used. In addition, pentazocine and/or buprenorphine were administered if necessary. There were no significant differences between the remimazolam and propofol groups in the use of pentazocine, buprenorphine, and remifentanil in this study.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Su K., Xue F.-S., Cheng Y. Comment on Matsumoto et al. Remimazolam’s Effects on Postoperative Nausea and Vomiting Are Similar to Those of Propofol after Laparoscopic Gynecological Surgery: A Randomized Controlled Trial. J. Clin. Med. 2023, 12, 5402. J. Clin. Med. 2024;13:923. doi: 10.3390/jcm13040923. [DOI] [PubMed] [Google Scholar]
  • 2.Gan T.J., Belani K.G., Bergese S., Chung F., Diemunsch P., Habib A.S., Jin Z., Kovac A.L., Meyer T.A., Urman R.D., et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth. Analg. 2020;131:411–448. doi: 10.1213/ANE.0000000000004833. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Medicine are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES